Is there a future for vaccination as a treatment for Alzheimer's disease?

Neurobiology of Aging

Volumn 24, Issue 3, 2003, Pages 391-395

  McGeer, Patrick L ^a   McGeer, Edith ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibodies; Complement; Inflammation; Microglia; Transgenic mice; Amyloid protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AN 1742; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DATA ANALYSIS; GENE INSERTION; HUMAN; IMMUNITY; IMMUNOSTIMULATION; INFLAMMATION; MEMBRANE; NERVE CELL NECROSIS; NEUROLOGICAL COMPLICATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE; VACCINATION;

EID: 0037405981     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00157-4     Document Type: Note

References (55)

1. Bard F., Cannon C., Barbour R., Burke R.I., Games D., Grajeda J.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. 6:2000;916-919.
2. Beyreuther K., Multhaup G., Masters C.L. Alzheimer's disease: genesis of amyloid. Ciba Found. Symp. 199:1996;119-127.
3. Bishop G.M., Robinson S.R., Smith M.A., Perry G., Atwood C.S. Call for Elan to publish Alzheimer's trial details. Nature. 416:2002;677.
4. Bornemann K.D., Wiederhold K.-H., Pauli C., Ermini F., Stalder M., Schnell L.et al. Aβ-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 158:2001;63-73.
5. Calhoun M.E., Wiederhold K.-H., Abramowski D., Phinney A.L., Probst A., Sturcher-Pierrat C.et al. Neuron loss in APP transgenic mice. Nature. 395:1998;755-756.
6. Das P., Minidis N. Effectiveness of Abeta1-42 immunization in the TG2576 mouse model using DNA vaccination. Neurobiol. Aging. 23:2002;S109.
7. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:2001;721-727.
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8850-8855.
9. Frangione B., Wisniewski T., Sifundsson E.M. A safer vaccine for Alzheimer's disease. Neurobiol. Aging. 23:2002;S432.
10. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K.et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152:1998;307-317.
11. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C.et al. Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
12. Ghochikyan A., Agadjanyan M.G. Different approaches to the development of vaccine against animal model of Alzheimer's disease. Neurobiol. Aging. 23:2002;S237.
13. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
14. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. IL-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
15. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
16. Hsaio K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S.et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
17. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:1997;965-973.
18. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E.et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6:2000;143-150.
19. Janus C., Pearson J., McLaurin J., Matthews P.M., Jiang Y., Schmidt S.D.et al. A beta-peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;970-982.
20. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
21. Joseph J.A., Shukitt-Hale B., Denisova N.A., Martin A., Perry G., Smith M.A. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol. Aging. 22:2001;161-163.
22. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C.et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 41:2002;922-928.
23. Klegeris A., McGeer P.L. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J. Leukoc. Biol. 67:2000;127-133.
24. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C.et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276:2001;12991-12996.
25. Lahita RJ, editor. The textbook of the autoimmune diseases. Philadelphia: Lippincott Williams & Wilkins; 2000.
26. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J.et al. Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79:2001;595-605.
27. Lim G.P., Yang F., Chen P., Beech W., Teter B., Tran T.et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model of Alzheimer's disease. J. Neurosci. 20:2000;5709-5714.
28. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 16:1996;5795-5811.
29. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M.et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158:2001;1345-1354.
30. Maruyama M., Arai H., Sugita M., Tanji H., Higuchi M., Okamura N.et al. Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease. Exp. Neurol. 172:2001;433-436.
31. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
32. McGeer P.L., Akiyama H., Itagaki S., McGeer E. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
33. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:1987;195-200.
34. McGeer P.L., Schwab C., Staufenbiel M., Hosakawa M. Amyloid transgenic mice: an incomplete model of Alzheimer's disease. Neurobiol. Aging. 23:2002;S234.
35. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dockey C., Hardy J.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
36. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D.et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
37. Mucke L., Shockley K., Essrich C., Yu G.-Q., Chang L., Lambert M.et al. Vaccination of human amyloid protein precursor transgenic mice with fibrillar Aβ or Aβ-derived diffusible ligands - can the immune response be focused on the real culprits? Neurobiol. Aging. 23:2002;S233.
38. Munch G., Robinson S.R. Alzheimer's vaccine: a cure as dangerous as the disease? J. Neural. Transm. 109:2002;537-539.
39. Akiyama H, Barger S, Barnum S, et al. (Neuroinflammation Working Group). Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
40. Perry G., Nunomura A., Raina A.K., Smith M.A. Amyloid-β junkies. Lancet. 355:2000;757.
41. Perry G., Raina A.K., Nunomura A., Wataya T., Sayre L.M., Smith M.A. How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic. Biol. Med. 28:2000;831-834.
42. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D.et al. Complement activation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10016-10020.
43. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
44. Shoji M., Kanai M., Matsubara E., Tomidokoro Y., Shizuka M., Ikeda Y.et al. The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently. Neurobiol. Aging. 22:2001;209-215.
45. Smith M.A., Atwood C.S., Joseph J.A., Perry G. Ill-fated amyloid-β vaccine. J. Neurosci. Res. 69:2002;285.
46. Smith M.A., Joseph J.A., Perry G. Arson: tracking the culprit in Alzheimer's disease. Ann. NY Acad. Sci. 924:2000;35-38.
47. Steinberg D. Companies halt first Alzheimer vaccine trial. The Scientist. 16:2002;22.
48. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S.et al. Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94:1997;13287-13292.
49. Tomidokoro Y., Harigaya Y., Matsubara E., Ikeda M., Kawarabayashi T., Shirao T.et al. Brain Aβ amyloidosis in APPsw mice induces accumulation of presenilin and tau. J. Pathol. 193:2001;500-506.
50. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K.et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
51. Webster S.D., Tenner A.J., Paulos T.L., Cribbs D.H. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol. Aging. 20:1999;297-304.
52. Weiss R. Test of vaccine to fight, Alzheimer's halted: inflammation in the brains of 12 volunteers quashes optimism. San Francisco Chronicle page A-3, 22 February 2002.
53. Wyss-Coray T., Yan F., Lin A.H.T., Lambris J.D., Alexander J.J., Quigg R.J.et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10837-10842.
54. Yasojima K., McGeer E.G., McGeer P.L. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer's disease. Brain Res. 833:1999;297-301.
55. Yasojima K., McGeer E.G., McGeer P.L. Relationship between beta-amyloid peptide generating molecules and neprilysin in Alzheimer's disease and normal brain. Brain Res. 919:2001;115-121.